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Abstract
Few studies have assessed whether mice used as cancer models experience pain. Despite
this possibility, the usual practice is to withhold analgesics as these are generally viewed as
confounding. However, pain also alters cancer progression, so preventing it might not only
be beneficial to welfare but also to study validity. Establishing the extent to which different
cancer models result in pain is an important first step towards their refinement. We used
conditioned place preference (CPP) testing and body-weight and behaviour analyses to
evaluate the assumption that heterotopically implanted tumours result in less pain and
fewer welfare concerns than those implanted orthotopically. C57Bl/6 mice received
MB49Luc luciferase expressing bladder cancer cells or saline implanted subcutaneously or
into the bladder. These tumour-bearing or control groups underwent 2 daily 45 minute con-
ditioning trials to saline or morphine (2mg/kg) and then a 15 minute drug-free preference
test on day 3 of a 3 day cycle, continuing until the study ended. Tumours were imaged and
behaviour data obtained following preference tests. Development of preference for the mor-
phine-paired chamber (morphine-seeking) was determined over time. Heterotopic tumour
development had no effect on morphine-seeking, and although the restraint used for hetero-
topic inoculation caused greater initial weight losses than anaesthesia, these mice steadily
gained weight and behaved comparatively normally throughout the study. Orthotopic
tumour inoculation caused no initial weight losses, but over the final 7 days these mice
became less active and lost more body weight than cancer-free controls. This indicated
orthotopic implantation probably caused a more negative impact on welfare or conceivably
pain; but only according to the current test methods. Pain could not be confirmed because
morphine-seeking in the tumour-bearing groups was similar to that seen in controls. Imag-
ing was not found to be an effective method of monitoring tumour development surpassing
manual tumour inspection.
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Introduction
With 50% of people now likely to experience cancer at some point in their lifetime [1] it is not
surprising that the numbers of mice used in cancer research has risen to over 400,000 annually
in the UK. Although many of these animals might develop pain, analgesics are rarely used as
they could confound results; for example by altering the baseline rate of tumour development.
Whereas non-steroidal anti-inflammatory drugs (NSAIDs) generally suppress tumour growth
[2–4], depending on the drug chosen and model type, opioids can either promote or suppress
various pathways involved in tumour progression [5–7]. Cancer researchers have to make vital
decisions as to how to minimise such confounds in order to maximise model validity and the
translational potential of findings. However, it can be forgotten that animals that are experienc-
ing pain could just as easily provide incorrect results; hence in some cases it might be a better
approach to try to prevent this. The route of cancer inoculation is another important issue in
undertaking such cost-benefit analyses. Heterotopic models usually involve subcutaneous inoc-
ulation, and although these are sufficient for preliminary trials, with regard to translational
value they are perceived to provide less relevant findings than orthotopic implants. This is
because orthotopic implants are into the tissue(s) of origin and development occurs in an
appropriate microenvironment; hence data on rates of angiogenesis, metastasis and the
responses to therapy are considered more informative [8, 9]. Heterotopic models are generally
viewed as more benign, so are seen to address researchers’ obligations to minimise suffering.
However, few studies have been undertaken to specifically determine the relative impact on
welfare of these different inoculation procedures. Monitoring aspects such as body weight,
behaviour and changes in peripheral nociception can provide early indications of problems or
evidence of pain [10, 11], but only indirectly. Developing effective monitoring tools has now
become even more important with the advent of new legislation requiring retrospective severity
assessment and more effective cost-benefit analyses (Directive 2010/63/EU). As a result, tests
aimed at determining how pain ‘affects’ animals [12–14], such as the Conditioned Place Prefer-
ence (CPP) procedure have grown more popular [15–19]. We have previously used this to
show that C3H/HeN mice orthotopically implanted with bladder cancer progressively show a
preference for a ‘place’ where they were exposed to morphine compared to one paired with
saline. Crucially, this increased morphine-seeking not only exceeded the morphine preference
of cancer-free controls, but was associated with heightened nociceptive responding and abnor-
mal behaviour, and was most obvious in mice with larger tumours [20]. These data provided
strong evidence of pain occurring up to 10 days before the study ended, and indicated a need
for end-point refinement. The current study used a similar approach to gain evidence of
whether pain might also arise in C57BL/6 mice during bladder cancer development, and as is
widely assumed, if such welfare concerns are lessened if tumours are implanted heterotopically.
Although there were more obvious impacts of orthotopic tumour development, for the reasons
discussed, the need for end-point refinement in studies involving orthotopic implantation of
bladder cancer in C57BL/6 mice remains uncertain.
Materials and Methods
Ethics Statement
All work was undertaken at the Comparative Biology Centre, Newcastle University, UK and
adhered to the ethical and legal obligations of the Animals (Scientific Procedures) Act 1986
(UK Home Office Project/Personal license numbers; PPL 60/4431 and PIL 60/13195), EU
Directive 2010/63 and the guidelines of the International Association for the Study of Pain
(IASP). Final approval was from the Newcastle University Animal Welfare Review Body.
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Animals
To prevent additional animal use, 80 female C57BL/6J surplus animals were supplied by
Charles River (Margate, Kent, UK). Forty were used in each study to match the design of our
previous study [20] where a power calculation was performed to establish the appropriate
numbers in each group. Mice in the heterotopic study were approximately 1–2 weeks younger
(7–8 vs. 8–9 weeks old). Females were used to compare with our previous investigation and to
reflect their more common use in bladder cancer studies due to the greater ease of urethral
catheterisation. They were provided with food (R&M no.3 SDS Ltd, Whitham, UK) and tap
water ad-libitum. They were singly housed in IVC cages (Type 1, (160mm (w) x 339mm (l) x
130mm (h)); Arrowmight, Hereford, UK) on sawdust bedding (Gold Chip, BS and S Ltd, Edin-
burgh, UK). ‘Sizzle nest’, a chew block and a cardboard tube provided enrichment (B&K Uni-
versal, Hull, UK). Acclimation was for 7 days in a holding room maintained at 23°C ± 1°C,
48% humidity, 15–20 air changes per hour and a 0700 to 1900 light cycle. Cages were cleaned
weekly, retaining some soiled bedding to maintain home-cage familiarity. The enrichment
materials were renewed as necessary. Once tumour development was confirmed (either via
imaging or palpation) the mice were supplied with 2–3 soaked diet pellets left on the bedding.
These were replenished each morning following weighing. Baseline weights were from the last
day of the acclimation period, and after this the mice were weighed between 8 and 10am every
morning.
Tumour inoculation
The tumour cells were donated by Dr Ariane Söling (MDKN, Göttingen, Germany). They were
cultured in Dulbecco’s Modified Eagle’s Medium (DMEM) supplemented with 10% foetal
bovine serum, 1% penicillin/streptomycin, and 0.1% sodium pyruvate (Invitrogen, Paisley,
Scotland). Assignment of mice for tumour implantation was based on the result of an initial
CPP preference test (described below). Details of the orthotopic implantation procedure can be
found elsewhere [20], but briefly, 2 batches of 20 mice were anaesthetised with isoflurane, and
then half of the mice in each batch (i.e. 10) were implanted in the bladder with 5x106 MB49Luc
cells in a solution of 50μl Dulbeccos’ Phosphate Buffered Saline (DPBS) using a 1ml syringe.
The remaining 10 mice of the batch were implanted with the same volume of DPBS only.
Syringes were secured to the tails with adhesive paper tape to leave the cells or DPBS in-situ for
60 minutes. After removing the syringes the mice recovered in an incubator set at 37°C for 30
minutes. The next batch of 20 mice was then anaesthetised and the implantation procedure
was repeated.
In the heterotopic study the 20 mice assigned for tumour inoculation were restrained for
subcutaneous (s/c) injection in the standard manner (http://www.procedureswithcare.org.uk/
subcutaneous-injection-in-the-mouse). An area of fur about 2 x 2 cm was then shaved on the
right flank midway between the fore and hind limbs before subcutaneously injecting 50μl of
DPBS containing 2.5x106 MB49Luc cells with an insulin syringe. The remaining 20 mice were
controls. These were shaved identically but injected with 50μl of DPBS. The orthotopically
inoculated mice received double the number of tumour cells in normal anticipation of a frac-
tion being voided in urine. Solutions were kept on ice but were warmed to body temperature
before use. After inoculation the mice were returned to their home-cages.
CPP Testing
Six identical CPP test units were used (Model 3013AT, Med Associates, St Albans, VT, USA).
Each unit had a black steel rod floored compartment (B) and a white steel grid floored com-
partment (W) separated by a grey solid-floored start box (G). The start box was separated from
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the B and W compartments by 2 programmable guillotine doors. Each compartment was
equipped with an infra-red array to record chamber residence times and the total numbers of
entries into and exits from each compartment. Initial preference testing was conducted one
day prior to tumour inoculation. For this, mice were placed into the start box in ambient light
for 1 minute following which the guillotine doors opened, the lights came on and the mice
explored the apparatus for 15 minutes. Aside from during the 1 minute acclimation interval all
chambers were equally illuminated at all times. The proportionate Black (B) or White (W)
chamber preference (Pref) was then calculated (e.g. BPref = tB/(tB+tW); where t = total cham-
ber residence time). Mice were randomly assigned to either the cancer or control group and for
saline or morphine conditioning in their least preferred chamber (S+), but ensuring the
between-group average B vs. W assignment was as close to 0.5 as possible [20]. Conditioning
began the day following implantation with 2 sessions each day for 2 days. A drug-free prefer-
ence test was conducted the next day (day 3) using the same method as for initial preference
testing. This 3-day cycle (2 conditioning days and then a preference test day) was repeated
until the study ended and the mice were euthanased. Black or white chamber conditioning was
to saline in the morning (S-) and then saline or morphine each afternoon (S+). Half of the con-
trol and half of the tumour mice therefore received saline under the S- and S+ conditions (10
mice each); and these acted as controls for the effect of morphine. Only giving morphine in the
afternoon was essential as there would otherwise have been carry-over effects from each morn-
ing conditioning session. All injections were given s/c. Morphine (Morphine sulphate, 30mg/
ml; NHS Supplies, UK) was diluted with water for injection and given at 2mg/kg (~0.03mls per
mouse). Saline controls received 0.03mls of 0.9% saline. Four hours elapsed between morning
S- and afternoon S+ sessions. Successive preference for the S+ chamber (on the third day of
each cycle) was calculated as for initial preference testing. The conditioning and test procedure
is depicted in Fig 1 of our previous article [20].
Behaviour analysis
The mice were filmed for behaviour analysis immediately after preference testing (between 2
and 4pm). Recordings only began once tumour development was confirmed either via imaging
or palpation. In the orthotopic investigation this was after 13 days, whereas in the heterotopic
study the first tumour was detected on day 3. Mice were placed into one of 3 clear plastic cages
(32cm x16cm x 13cm, Techniplast UK Ltd) containing only sawdust bedding. They were
recorded for 10 minutes using a video camera (Sony DCR-HC96, Sony, Japan) fixed to a tripod
and positioned 30cm from the cage front. Cages were wiped with 70% ethanol between record-
ings. The video footage was analysed using automated behavioural analysis software (HomeCa-
geScan; Clever Systems Inc., VA, USA (HCS). Details on this can be found elsewhere [20–24].
Imaging
After filming, the mice were returned to their home-cages and moved a short distance to a
room housing an IVIS Spectrum 200 (Xenogen, USA). They were injected s/c with 150mg/kg
D-Luciferin (PerkinElmer, UK) and placed back into their home-cages. Mice were imaged 12
minutes later in groups of 3 or 4 following induction of anaesthesia with 5% isoflurane in 2
litres/min oxygen. The results section describes how a 12 minute delay was confirmed as the
time of peak bioluminescent signal intensity. They were placed in the IVIS machine in dorsal
recumbency on a stage heated to 36°C and anaesthesia was maintained by face-mask delivery
of 2% isoflurane in 1.5–2 litres/min oxygen. Open filter scans of the appropriate body region
(bladder or flank) were acquired with subject depth set at 1.5cm and exposure time set auto-
matically. After imaging the mice recovered in their home-cages. The cancer-bearing mice
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were imaged every 3 days along with a randomly selected representative number of controls (5
conditioned to morphine and 5 to saline).
Monitoring and end-point determination
Mice were checked for signs of tumour growth during daily weighing. Tumours implanted
heterotopically were measured according to their length and width using digital calipers
(‘Absolute Digimatic’; Mitutoyo Ltd., Andover, UK). The orthotopically implanted tumours
were assessed by an experienced technician (CH) by gentle palpation of the bladder region
between the thumb and forefinger. General condition was assessed each day; e.g. if mice
appeared lethargic or had any mobility issues. Mucous membranes were inspected for normal
appearance, and the coat for any piloerection or lack of grooming or dehydration (fur pinch
test). In the orthotopic study any hematuria was noted whilst palpating the bladder, or if there
was blood stained fur or bedding. Mice were earmarked for euthanasia once tumours were
estimated to be in excess of 1cm diameter, or if there was>15% body weight loss and/or if
they showed at least 2 of the clinical symptoms described above. In the heterotopic study mice
were euthanased once tumours were>12mm at their widest point, if they lost>15% body
weight, or if either of these coincided with any obvious lack of mobility. The decision to eutha-
nase was made by consulting with the chief area technician (CH), NACWO or facility
veterinarian.
Nociceptive testing
Mice deemed close to end-point underwent nociceptive testing (Hargreaves method [25]) to
determine their final nociceptive status. The decision as to whether it was humane to undertake
this testing was made by the experienced technician (CH) or attending veterinarian. This was
only allowed if mice were still mobile and responsive when examined by handling. Although
there was no plantar injury caused by tumour growth, thermal response thresholds can alter
due to the phenomenon of referred hyperalgesia. This can be used as an indirect method of
assessing underlying pain status as has previously been shown during tumour development in
mice [26] and in visceral pain models in rats [27–29]. The test apparatus had 6 clear plastiglas
enclosures (11cm x 17xm x 14cm) in which mice acclimated for 3–5 minutes. The plantar test
was then applied (Ugo Basile, Italy: Model 37370) with a heat intensity of 280mW/cm2 (30s
cut-off time). Three readings were obtained from each hind-paw when mice were stationary
and not grooming, alternating between paws and allowing at least 2 minutes between succes-
sive ipsilateral recordings. Faeces and urine were removed with a damp paper towel as neces-
sary. They then received 2mg/kg morphine subcutaneously and were returned to their home-
cages for 20 minutes. The enclosures were cleaned with a damp paper towel and then the test
procedure was repeated.
Euthanasia and post-mortem assessment
Mice were euthanased by cervical dislocation either immediately after completing nociceptive
data collection, or if it was an imaging day, they were imaged and then overdosed with isoflur-
ane in the IVIS machine before cervical dislocation. Primary tumours were immediately
removed, measured and weighed and then imaged both intact and after being dissected in half
using the same settings as for whole body imaging. The carcasses were then imaged to identify
any metastases. A general inspection was then carried out following which the major organs
including the heart, lungs, liver and kidneys were removed and weighed.
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Data processing
In the orthotopic study data collection continued in all control mice until the last tumour bear-
ing animal was euthanased; matching our previous CPP bladder study design in C3Hmice [20].
With hindsight this was unnecessary, so to reduce the burden of testing to the animals in the het-
erotopic study a randomly selected treatment-matched control was euthanased alongside each
tumour-bearing animal. Analyses focused on the periods of potentially greatest impact on wel-
fare; following tumour inoculation and approaching euthanasia (i.e. when tumours were most
developed). Before first tumour detection the available data were compared between studies
directly. However, because mice were euthanased at different times during the period approach-
ing euthanasia these data were processed as we have previously described [20]. This was by
aligning data from tumour-bearing animals with those from the same elapsed study time in ran-
domly selected treatment-matched controls. In both studies the first mouse was euthanased after
6 CPP tests. Since the first test was on day 3, this was a total of 18 days. The last 6 CPP test cycles
required a total of 16 days, so data spanning these two phases were used to assess welfare
changes. The CPP outputs were; the proportionate total S+ chamber residence times, explora-
tions (breaks of the first chamber beam), entrances (beams broken beyond the first), activity
(any chamber beam break) and movements (a change in beams broken). The behaviour data
underwent an initial analysis to identify the activities changing most due to tumour progression.
Further details on this can be found elsewhere [20]. Relative changes in baseline body weight
were calculated and were adjusted for final tumour wet-weight. Rates of tumour development
were calculated as final wet-weight/total days, and final tumour burden as a proportion of final
body weight. In the heterotopic study, tumour growth results were also available from the caliper
measurements. The Hargreaves data were assessed according to mean response latency over the
3 left or right paw readings, and also the overall mean latency before and following morphine.
Statistical analysis
All data were analysed using SPSS statistics software (IBM; Version 22). They were tested for
normality and homogeneity of variance before applying GLM repeated measures with ‘Time’
as a within-subjects factor and cancer vs. control and morphine vs. saline as between-groups
factors. Analyses were applied to the data obtained over the first 18 or last 16 days (each span-
ning 6 CPP tests). Correlation analysis (Pearson’s ‘r’) was used to assess relationships between
morphine seeking and the kidney, tumour and body weight data, and if there were links
between these and final tumour burden. Paired samples t-tests were used to analyse the noci-
ceptive response data with probability levels corrected for multiple comparisons (Bonferroni)
as appropriate. All Figs show mean values ±1SEM whereas values shown in the text and S1
Table are means ±1SD. A copy of the original data can be found in S1 Data.
Results
There was no significant difference in the total number of days mice were enrolled following
heterotopic or orthotopic tumour implantation (40±9 vs. 35±10 days), and this was also unaf-
fected by whether mice received morphine. Tumour inoculation failed in 3 orthotopically
implanted mice; 2 assigned for morphine and 1 for saline conditioning. Data from these 3 mice
were therefore excluded.
Body weight
One mouse in the heterotopic study was 5g lighter at baseline than all others so was excluded.
Otherwise there were no significant differences in baseline body weights across the four
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treatment groups in each study. However, the mice in the heterotopic study were 1 week youn-
ger and initially weighed less (18±0.2 vs. 23±0.3g; f(1, 78) = 176, p<0.001). In the orthotopic
study there were no weight differences over the first 18 days regardless of whether mice
received morphine or a tumour, however ‘Time’ was significant (F(15, 495) = 12.5, p<0.001).
This was because weights generally increased over the first 5 days (F(1, 74) = 40, p = 0.001),
and following this there were either gains or small losses (Fig 1a). In the heterotopic study
‘Time’ was also highly significant as mice lost weight over the first 3 days but then also steadily
gained (F(15, 525) = 64.4, p<0.0001). However, those receiving morphine showed greater ini-
tial losses (day 1–3) and then more rapid gains than those conditioned to saline; significant
‘Time’ x ‘Morphine’ interaction (F(15, 525) = 2.1, p = 0.009). Gains were also less rapid if mice
were tumour-bearing; ‘Time’ x ‘Tumour’ was significant (F(15, 525) = 4.4, p<0.001; Fig 1b).
The same analysis was applied to data from the last 16 days. In the orthotopic study the con-
trols gained whereas the tumour-bearing mice lost between 5 and 10% (significant ‘Time’ x
‘Tumour’ interaction; F(15, 525) = 9.5, p<0.001, Fig 1c), and this was unaffected by morphine.
Fig 1. Body weight results.Mean percentage changes from baseline (pre-inoculation) body weight (±SEM) in mice inoculated with MB49luc bladder
cancer (Tum) or DPBS (Ctrl) and conditioned to morphine (Mor) or saline (Sal). Panels respectively illustrate data spanning the first 18 days (6 CPP
Tests) and the final 6 CPP tests prior to euthanasia (16 days) in mice inoculated orthotopically (a, b) or heterotopically (c, d).
doi:10.1371/journal.pone.0158390.g001
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In the heterotopic study all mice showed steady weight gains; also without any effects of mor-
phine (‘Time’ significant (F(15, 540) = 39, p<0.001; Fig 1d).
CPP
There were no significant CPP changes over the first 6 test cycles in either study depending on
whether mice received morphine or were tumour-bearing. Over the last 6 tests (16 days) S+
chamber residence times increased in mice orthotopically implanted with tumours and condi-
tioned to morphine, however, this was rendered non-significant as the same occurred over the
last 2 tests in the saline-conditioned tumour group (Fig 2a). In the heterotopic study morphine
had no overall effect; S+ scores increased over the last 2 tests in controls but reduced in the
tumour groups (Fig 2b). Although both tumour groups showed a reduced S+ preference over
these final 2 tests (‘Tumour’ factor significant (F(1, 37) = 13.6, p = 0.001)), this was not accom-
panied by increased time spent in the central grey zone. Had this been the case it might have
indicated the mice had mobility issues. The other CPP measures (exploratory movements and
entrance counts) were no more informative that total residence times so have not been depicted
graphically.
Behaviour
There were no significant behaviour alterations in either study prior to the last 16 days (6 CPP
tests) and no effects of morphine. The only activities that were significantly impacted during
this later phase of tumour development were low and high rearing. These were averaged and
compared between groups. Heterotopic implantation caused no significant behaviour changes
as the study approached end-point (Fig 3). Compared to controls the tumour-bearing mice
implanted orthotopically progressively reared less over the last 3 CPP tests (7–10 days; ‘Time’ x
‘Tumour’; (F(5, 175) = 2.5, p = 0.031), although this was only a modest overall difference.
There was no evidence indicating the anaesthesia sessions used for imaging had any influence
Fig 2. CPP results. Proportionate S+ chamber residence time (mean ±SEM) over the final 6 CPP cycles (P_6 to P_1; 16 days) before euthanasia in mice
inoculated orthotopically (a) or heterotopically (b) with MB49luc bladder cancer (Tum) or DPBS (Ctrl) and conditioned over a repeated 3 day cycle to
morphine (Mor) or saline (Sal).
doi:10.1371/journal.pone.0158390.g002
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on behaviour; i.e. the 10 non-tumour imaging controls behaved in the same way as their non-
imaged counterparts.
Tumour development
Imaging was the main method of monitoring tumour growth, but in the heterotopic study
tumours were also measured using calipers. Determination of the luciferin kinetic curve
showed mean TF steadily increased until 12 minutes after luciferin administration, plateaued
at 132±158 photons/second and then increased from 14 to 20 minutes to 148±176, but by then
the signals were generally more variable. A 12 minute delay was therefore appropriate and was
used in all cases. None of the controls showed any above-background signal at any time. Fig 4a
shows the orthotopic and heterotopic imaging data from the first 6 CPP tests in the saline or
morphine groups. Multiple comparisons were used to compare results between successive
imaging days. In the orthotopic study bioluminescent signals were slow to develop, and it took
until day 15 (CPP Test 5) before they were above that measured on day 6 (p = 0.007). After this
they were highly variable, especially in the mice receiving morphine, and as a result the mean
increase to day 18 was not significant. Heterotopic signal intensity increased from day 3 to 9 (F
(1, 18) = 18.9, p<0.001), especially in mice receiving morphine (‘Time’ by ‘Morphine’ (F(5, 90)
= 2.5, p = 0.037). This effect of morphine was most pronounced on imaging day 3 (elapsed day
9), but after this all signals declined dramatically. The results from the last 6 imaging sessions
were also highly varied. The highest signal intensity was in the orthotopic study between tests 3
and 4 before euthanasia, which then significantly declined (‘Time’; F(5, 70) = 2.7, p = 0.027; Fig
4b). Although there was no overall effect of morphine, post-hoc analysis indicated enhanced
signal intensity in the orthotopic mice receiving morphine spanning tests days 6 and 4 prior to
euthanasia (F(1, 14) = 6.6, p = 0.022). The heterotopic results showed the same pattern; a
Fig 3. Behaviour results. The mean frequency of rearing (±SEM) in the orthotopic (left axis; circles) and
heterotopic study (right axis; triangles) in tumour bearing and control groups (filled versus open symbols);
showing the significantly greater decline in activity in the tumour-bearing mice in the orthotopic study from
CPP test 3 (P_3) to just prior to euthanasia (P_1).
doi:10.1371/journal.pone.0158390.g003
Welfare Assessment following Heterotopic or Orthotopic Inoculation of Bladder Cancer in C57BL/6 Mice
PLOS ONE | DOI:10.1371/journal.pone.0158390 July 27, 2016 9 / 17
modest signal increase from tests 6 to 4 followed by a significant decline towards the study end
(‘Time’; F(5, 90) = 2.9, p = 0.016), but without any obviously greater intensity in mice given
morphine. Fig 4c and 4d show the caliper–based estimates of heterotopic tumour size as the
study progressed. Despite the apparent decline in TF in the imaging data, tumours steadily
continued to develop over the first 18 days (‘Time’ significant (F(15, 270) = 22.78, p<0.001),
and after day 12 tumours were clearly enhanced by morphine (CPP Test 4 onwards; (‘Time’ x
‘Morphine’; (F(15, 270) = 2.95, p<0.001); Fig 4c). The last 16 days (last 6 CPP/imaging cycles;
Fig 4d) saw a significant increase in tumour growth until the study ended (‘Time’ significant;
(F(15, 270) = 20.5, p<0.001), and although tumours were estimated as larger in the morphine
group, not significantly. Haematuria was eventually observed in all orthotopically implanted
mice with blood stained bedding and blood often being noted during palpation. This was first
observed in one mouse on post-implantation day 11. Although this was not directly quantified
Fig 4. Imaging results. (a) the mean total flux (TF ±SEM) of bioluminescent signals emanating from tumours implanted orthotopically (Orth; left axis,
circles) or heterotopically (Het; right axis, triangles) in mice conditioned to morphine (Mor; closed symbols) or saline (Sal; open symbols) and imaged
every 3 days (beginning on day 3) for 18 days (Day_CPP Test); (b) Mean TF (±SEM) during the final 6 CPP tests (P_6 to P_1; 18 days) before
euthanasia; (c) Caliper measurements showing the mean tumour surface area (mm2 ±SEM) of heterotopically implanted tumours over the first 18 post-
inoculation days (6 CPP tests) and (d) last 16 days (6 CPP tests) in mice conditioned to morphine or saline.
doi:10.1371/journal.pone.0158390.g004
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it was used alongside the body-weight changes and the other clinical symptoms to inform end-
point decisions.
Nociceptive testing
Thermal responding was conducted on euthanasia days if possible. Paired t-tests indicated the
mean of the 3 readings from the left and right paws was similar so the grand mean (left/right)
was used in all analyses. The pre-morphine response latencies were similar between the tumour
and control mice in both studies, and there was no evidence that this was affected by prior
exposure to morphine (i.e. during conditioning). Morphine caused a general increase in noci-
ceptive response latencies, but this was only significant in the orthotopic study (‘Time’ signifi-
cant; (F(1, 31) = 9.8, p = 0.004). There was also no evidence of differentially lesser or greater
responding depending on whether mice were implanted orthotopically or heterotopically.
Post-mortem assessments
There were no metastases in either study and no obvious effects on any organ other than the
kidneys in mice implanted orthotopically. The kidneys of these mice were significantly
enlarged relative to controls (F(3, 36) = 3.7, p = 0.021) especially in mice with larger tumours
(Pearsons’s R = 0.73, p = 0.001). Neither study showed a significant difference in final tumour
wet-weights between the morphine or saline groups. The mean weight of orthotopically
implanted tumours was 0.3±0.1g in both groups, and in the heterotopic study was 0.2±0.1g in
the saline group and 0.4±0.1g in the morphine group. Rate of tumour development (weight/
study days) and weight calculated as a proportion of final body weight also showed no signifi-
cant overall effect of morphine. Final tumour wet-weights did not significantly correlate with
either end-stage behaviour change or nociceptive status in either study.
Discussion
Mice are an invaluable resource for developing treatments for human cancer, but are used at
the potential cost of uncontrolled pain or generally poor welfare. Previously we used CPP
testing and behaviour analysis to show C3H/HeN mice probably experience pain following
orthotopic implantation of bladder cancer [20]. However, mouse strains are known to be dif-
ferentially sensitive to pain [30], so in this investigation we attempted to establish if this also
applies to C57BL/6 mice. We assessed two tumour inoculation methods predicting that ortho-
topically implanted tumours would more severely affect welfare; i.e. as these tumours grew
there would be greater morphine-seeking and larger scale behavioural alterations and body-
weight losses.
The main methodological difference from our previous study was that we used another
non-metastasising bladder cancer cell line allowing tumours to be imaged. Compared to pal-
pating tumours this was supposed to allow us to more precisely relate tumour growth stage to
welfare status. However, the imaging results were generally unreliable as a means of monitoring
development. For example, the first 9 days of the heterotopic study saw a particularly rapid sig-
nal increase in mice receiving morphine. Although this may have been due to an initial facilita-
tion of luciferin uptake by tumours, and was a probable early indicator of the known pro-
angiogenic effects of morphine [31], it was subsequently lost. The orthotopic signals were also
variably affected by morphine; although at certain times they were increased, they were ulti-
mately not indicative of eventual tumour burden assessed at autopsy. Post-mortem tumour
imaging showed tumour necrosis was the most likely reason for this, and although there was
no evidence this was affected by morphine, it has been found to be a problem with other lucif-
erase-expressing orthotopic bladder cancers in mice [32], including the MB49 cell line [33].
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Despite the imaging results, however, the post-mortem inspections confirmed tumours had
continued to grow, and based on the heterotopic caliper estimates that they were indeed
enhanced by morphine (Fig 4c and 4d). Although this was previously not found following
orthotopic implantation of MBT-2 tumours, it may have been missed since at that time palpa-
tion was the only method of assessing tumour development. Although the mechanism by
which opiates alter tumour growth is not fully understood, immune system suppression has
most frequently been implicated where more rapid development occurs [34, 35]. The impact of
morphine was not presently reflected in the tumour wet-weights, possibly because of desicca-
tion during the more time-consuming process of removing and dissecting larger tumours.
The morphine dose rate was 2mg/kg throughout both investigations. This was based on our
previous finding that at this dose it has no major rewarding effects but is still analgesic in C3H/
HeN orthotopically implanted with a similar type of bladder cancer [20]. In that study cancer-
related pain was indicated by increased morphine seeking coinciding with reduced active
behaviour and body-weight over a similar study time-scale. Here, there was also an increased
CPP to morphine as the orthotopic study ended, and the mice again lost body-weight and
became less active. There was also the expected absence of, or reduction in morphine-seeking
in cancer-free controls despite reducing the time of each CPP test from 45 to 15 minutes. In
our previous study we hoped using 45 minute test cycles (but using only the first 15 minutes of
data from each test) would add an essential extinction component. Then, by minimising the
morphine preference of the controls we hoped to be able to more clearly distinguish any nega-
tively reinforcing effects of morphine in the orthotopically implanted cancer group. However,
this was subsequently not found to be helpful so preference tests were currently set to be 15
minutes only. An important study aim was to evaluate whether using the CPP approach might
resolve some uncertainties as to the pain susceptibility of B6 mice. However, the current final
preference of B6 mice for morphine in the orthotopic cancer group was more variable than pre-
viously found in C3H mice, and the total scores also averaged lower; reducing confidence that
these end-stage effects were linked to pain in this strain also. Apart from our own previous
work we know of only one other example where CPP testing has been applied to investigate the
morphine preferences of B6 mice bearing orthotopically implanted tumours. Betourne et al.
[36] found melanoma caused reduced morphine preference, and proposed that this was due to
anti-opioid neuropeptide-related suppression of morphine reward. However, they used a sub-
stantially different study design to ours; a five-fold larger drug dose given on four occasions fol-
lowed by a single preference test. Although it would be unwise to suggest a similar process
occurred here, given the similarities between our previous orthotopic study in C3H mice it was
still surprising that the B6 mice did not show similarly elevated morphine-seeking by the study
end-point. Although B6 mice are sensitive to the positively reinforcing effects of morphine [37,
38], they have been found to respond more variably to different types of nociceptive stimuli
than many other commonly used strains [30, 39]. It is possible, therefore, that in terms of
‘affect’ that they are either less or more variably reactive to the negatively reinforcing (i.e. pain-
preventative) properties of morphine than some other strains.
With a view to informing future cost-benefit assessments the most important aim was to
assess the effects of orthotopic relative to heterotopic tumour development in terms of impact
on mouse welfare. We challenged the assumption that heterotopic models raise fewer concerns,
such that in circumstances where translational potential is non-essential they are preferable to
orthotopic models. Although the findings were not sufficient to say heterotopic implantation
caused less pain, there were some obvious and at least one unexpected difference between the
two models. The orthotopically implanted mice lost more weight as tumours grew and they
became behaviorally less active; both of which are indicators previously taken as evidence of
pain or another negatively affective state in mice [20, 40–42]. Orthotopic tumours also caused
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haematuria and enlarged kidneys, whereas in the heterotopic study, not only were there no
major behaviour alterations but no end-stage weight losses. One might assume conditions
causing hydronephrosis, including bladder cancer, would be painful. However, this is only
described as painful by 26% of humans, and only if the cause has a rapid onset; e.g. the forma-
tion of renal calculi [43] which also causes obvious signs of pain in rats [29]. The most obvious
conclusion from these collective findings is that orthotopic implantation, if not painful, was
more stressful.
Hargreaves testing was intended to provide supplementary evidence of pain status such that
mice with orthotopic tumours might become more nociceptive or differentially responsive to
morphine. However, we observed only the typical opioid-induced increase in response latency
without any model differences or relationship to eventual tumour burden; hence these data
were less helpful than previously [20]. As is common, body-weight changes were used as a gen-
eral indicator of welfare status. The restraint used for heterotopic tumour inoculation caused
more initial losses, but once this weight was recovered these mice gained weight more rapidly;
possibly because they were initially younger. However, offsetting these losses against an under-
lying more rapid growth rate means the initial effect of restraint may have been underesti-
mated. Considering stress is a well-documented contributor to tumour growth variation, in
terms of future study refinement anaesthesia may be more suitable than restraint as a means of
immobilising animals for tumour implantation.
Although we have found no evidence that our present Home Office project severity banding
of ‘moderate’ should be altered, it is still possible that individual mice, especially those with
larger orthotopic tumours may have been more painful depending on the particular bladder or
upstream region affected. This, therefore, does not point to any reduction in efforts to deter-
mine whether these and other mouse cancer models require refinement; for example by with-
drawing animals earlier, or providing pain relief. The present use of morphine had some
confounding effects, but with more uniform tumour development the Conditioned Place Pref-
erence testing procedure should still be a useful method of determining at what stage tumours
affect welfare. In future studies we would therefore consider using an alternative drug for con-
ditioning. Buprenorphine, for example, is both rewarding and analgesic in mice [41, 44], and
in a recently completed study in BALB/c mice we have found it to be protective against surgical
stress-induced proliferation of orthotopically implanted mammary carcinoma (unpublished
results). As against this, it can increase metastatic colonization of the lungs so would be inad-
visable for use in pain testing in immunocompromised mice [45]. Also, as with other assess-
ment methods the value of the CPP approach towards welfare and end-point refinement may
be highly strain dependent; given that van Loo et al., for example [46] found buprenorphine to
have limited pain relieving properties in DBA/2 mice. We would not consider using NSAIDs
since these generally impede tumour development [2–4], and because achieving effective pain
relief is difficult even with excessively large dose rates of this class of drug [23, 40, 42, 47].
Although there could be disadvantages to using buprenorphine it at least seems to have fewer
impacts on the immune system, which could explain why it has fewer overall effects on tumour
development than some other opioids [5, 6].
Finally, it is important to say why the mice were housed singly and why they were female.
Single housing the mice was not a decision taken lightly since these are social animals that
are susceptible to isolation stress. This was done in an attempt to acclimate the mice to the
environment they would be exposed to in the CPP apparatus, whilst collecting the behaviour
data and during induction of anaesthesia before imaging. It also meant it was not necessary to
perform ear-notching; which probably results in initial stress, and from which it is still not
known how long mice need to recover. Using group-housed individually marked mice would
have made it more difficult to select the correct individual from each cage at the appropriate
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time-point. This inevitably takes longer and requires additional handling and ‘cage-searching’,
and may have significantly raised the chances of errors that could have virtually invalidated the
results. Although they were alone, they were in semi-transparent cages adjacent to each other,
consequently it was hoped any isolation stress would have been minimal. Females were used
since apart from being an extension of our previous work [20] it is still not known how female
mice differ from males in terms of sensitivity to circumstances eliciting poor welfare or pain
[48]. Since there will inevitably be circumstances where female mice are necessary (e.g. studies
of mammary carcinoma) these uncertainties can only persist if studies generally only ever use
males.
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